menu
    • menu

    Company profile for Sosei Group Corporation

    NEW Drugs in Dev: 21
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Sosei Heptares is an international biopharmaceutical group focused on the design and development of new medicines originating from its proprietary GPCR-targeted StaR® technology and Structure-Based Drug Design platform capabilities. We are advancing a broad and deep pipeline of partnered and in-house drug candidates in multiple therapeutic areas including neurology, immuno-oncology, gastroenterology, inflammation and rare/spe...
    Sosei Heptares is an international biopharmaceutical group focused on the design and development of new medicines originating from its proprietary GPCR-targeted StaR® technology and Structure-Based Drug Design platform capabilities. We are advancing a broad and deep pipeline of partnered and in-house drug candidates in multiple therapeutic areas including neurology, immuno-oncology, gastroenterology, inflammation and rare/specialty diseases.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Sosei Group Corporationjapan Flag
    Country
    Country
    Japan
    Address
    Address
    PMO Hanzomon 11F 2-1 Kojimachi, Chiyoda-ku Tokyo 102-0083
    Telephone
    Telephone
    +81 (0)3 5210 3290
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://soseiheptares.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    German Wound Congress

    German Wound Congress

    Not Confirmed

    envelop Contact Supplier

    German Wound Congress

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Nxera Pharma Q1 2026 Operational Highlights & Results
    Nxera Pharma Q1 2026 Operational Highlights & Results

    01 May 2026

    // FIRSTWORD PHARMA

    https://firstwordpharma.com/story/7259104

    FIRSTWORD PHARMA
    01 May 2026
    Share Share
    Company Issues New Shares for ESOP, RSU Awards
    Company Issues New Shares for ESOP, RSU Awards

    15 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/15/3274145/0/en/Notice-of-Issuance-of-New-Shares-in-Connection-with-the-Introduction-of-the-Employee-Stock-Ownership-Plan-Matters-Relating-to-Stock-Units-and-Determination-of-Payment-Amount-and-Ot.html

    GLOBENEWSWIRE
    15 Apr 2026
    Share Share
    Nxera Pharma's QUVIVIQ Approved In Taiwan For Insomnia
    Nxera Pharma's QUVIVIQ Approved In Taiwan For Insomnia

    14 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/14/3273091/0/en/Nxera-Pharma-s-QUVIVIQ-daridorexant-25mg-and-50mg-Receives-Approval-in-Taiwan-for-the-Treatment-of-Insomnia.html

    GLOBENEWSWIRE
    14 Apr 2026
    Share Share
    Nxera Pharma Initiates Phase 2 Trial Of NBI-1117570
    Nxera Pharma Initiates Phase 2 Trial Of NBI-1117570

    12 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/12/3272170/0/en/Nxera-Pharma-s-Partner-Neurocrine-Biosciences-Doses-First-Patient-in-Phase-2-Trial-of-NBI-1117570-for-Adults-with-Schizophrenia.html

    GLOBENEWSWIRE
    12 Apr 2026
    Share Share
    Nxera Pharma Achieves 2nd Metabolic Milestone With Lilly
    Nxera Pharma Achieves 2nd Metabolic Milestone With Lilly

    08 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/08/3270611/0/en/Nxera-Pharma-Achieves-Second-Development-Milestone-in-Collaboration-with-Eli-Lilly-Targeting-Metabolic-Diseases.html

    GLOBENEWSWIRE
    08 Apr 2026
    Share Share
    Nxera Pharma To Get $3M Milestone Payment From Centessa Pharma
    Nxera Pharma To Get $3M Milestone Payment From Centessa Pharma

    05 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/05/3249876/0/en/Nxera-Pharma-to-Receive-US-3-Million-Milestone-Payment-from-Centessa-Pharmaceuticals.html

    GLOBENEWSWIRE
    05 Mar 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search